Endoscopy 2024; 56(S 02): S154
DOI: 10.1055/s-0044-1783026
Abstracts | ESGE Days 2024
Moderated Poster
EUS-guided tissue acquisition and ablation for pancreatic lesions 25/04/2024, 08:30 – 09:30 Science Arena: Stage 1

Diagnosis of pancreatic solid lesions by ultrasound endoscopy fine-needle biopsy with Franseen needles: macroscopic on-site (MOSE) versus rapid on-site (ROSE) evaluation. Is the pathologist necessary in the endoscopy suite?

E. Pijoan Comas
1   Clínica Girona, Girona, Spain
2   Hospital de Palamós, Palamós, Spain
,
D. Vazquez Gomez
3   Hospital Universitari Arnau de Vilanova, Lleida, Spain
,
N. Zaragoza Velasco
3   Hospital Universitari Arnau de Vilanova, Lleida, Spain
,
A. L. Vargas García
1   Clínica Girona, Girona, Spain
2   Hospital de Palamós, Palamós, Spain
,
M. Alburquerque Miranda
1   Clínica Girona, Girona, Spain
2   Hospital de Palamós, Palamós, Spain
,
N. Torres Monclus
3   Hospital Universitari Arnau de Vilanova, Lleida, Spain
,
M. Figa Francesch
1   Clínica Girona, Girona, Spain
,
R. Ballester-Clau
3   Hospital Universitari Arnau de Vilanova, Lleida, Spain
,
M. Planella De Rubinat
3   Hospital Universitari Arnau de Vilanova, Lleida, Spain
,
F. González-Huix Lladó
1   Clínica Girona, Girona, Spain
3   Hospital Universitari Arnau de Vilanova, Lleida, Spain
› Author Affiliations
 
 

    Aims The evaluation of biopsy samples obtained with fine-needle biopsy (FNB-EUS) using Franseen needles by ultrasound endoscopy by endoscopist (Macroscopic On-Site Evaluation: MOSE) improves the diagnostic accuracy of pancreatic solid lesions. The achievement of macroscopic visible core (MVC)>4mm has a high diagnostic accuracy with MOSE.

    Aim: To compare diagnostic accuracy of Rapid On-Site Evaluation (ROSE) and MOSE by endoscopist in pancreatic solid lesions.

    Methods Prospective bicentric study, consecutive recruitment of patients with pancreatic solid lesions in 2 general hospitals (MOSE was performed in hospital A and ROSE in hospital B). Franseen needles were used (Adquire, Boston Scientific). We evaluated: 1) diagnostic achievement and accuracy (including sensitivity, specificity, positive predictive value and negative predictive value) in solid pancreatic lesions; 2) MVC>4mm acquisition; and 3) number of needle passes needed with MOSE vs ROSE.

    Results A total of 132 patients were included (33 women, 68 men, median age 68,2±1,025). MOSE was performed in 90 (68.2%) and ROSE in 42 (31.8%); in 110 (83.3%) malign and 22 (16.7%) benign pancreatic solid lesions. Correct diagnosis by EUS-FNB was achieved in 89.4% patients (with MOSE 88.8%; and ROSE 92.9%; p=0.54). Sensitivity was 100%, specificity 89%, PPV 81.3% and NPV 100% (with MOSE: sensitivity 100%, specificity 87.5%, PPV 88.8% and NPV 100%; with ROSE: sensitivity 100%, specificity 92.1%, PPV 92.6% and NPV 100%). MVC>4mm was obtained in 72.7% (71.1% in MOSE, 76.2% in ROSE, p=0.67). There were no statistically significant differences in diagnosis achievement between MVC>4mm and<4mm (88.6% in MOSE and 90.6% in ROSE, p=0.74). No differences in number of passes necessary to achieve diagnosis was found between MOSE and ROSE.

    Conclusions Evaluation of biopsy simples of pancreatic solid lesions obtained by FNB-EUS with Franseen needles by endoscopist (MOSE) has a diagnostic accuracy similar to ROSE, making unnecessary the presence of a pathologist in the endoscopy suite.


    #

    Conflicts of interest

    Authors do not have any conflict of interest to disclose.

    Publication History

    Article published online:
    15 April 2024

    © 2024. European Society of Gastrointestinal Endoscopy. All rights reserved.

    Georg Thieme Verlag KG
    Rüdigerstraße 14, 70469 Stuttgart, Germany